Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 8, 2021, the compensation committee (the "Committee") of the board of directors (the "Board") of Athira Pharma, Inc. (the "Company") approved 2020 bonus payments for the Company's executive officers as set forth in the table below. The Committee approved the bonus payments in recognition of the executive team's achievements in 2020, including the advancement of the Company's product candidates and completion of certain financing and other corporate objectives.





     Name                 Title                                    2020 Bonus
     Dr. Leen Kawas       President and Chief Executive Officer   $    357,000
     Ms. Glenna Mileson   Chief Financial Officer                 $    215,600
     Dr. Hans Moebius     Chief Medical Officer                   $    190,120
     Dr. Mark Litton      Chief Operating Officer                 $    172,000
     Dr. Kevin Church     Vice President of Discovery             $     57,500

Item 7.01 Regulation FD Disclosure.

Commencing on or after January 11, 2021, members of the Company's management will be providing a corporate update to analysts and investors through a series of one-on-one meetings.

The information in Item 7.01 of this Current Report on Form 8-K, including the slides to be used in such one-on-one meetings attached as Exhibit 99.1 hereto, are being furnished and not filed pursuant to Item 7.01 of Form 8-K. Such information shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



            Exhibit No.   Description

            99.1            Athira Pharma, Inc. Presentation Slides




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses